Apple settles its 2-year intellectual property lawsuit with Qualcomm by agreeing to a multi-year patent license.

Charlene Vos

2019-05-01 09:27:00 Wed ET

Apple settles its 2-year intellectual property lawsuit with Qualcomm by agreeing to a multi-year patent license with royalty payments to the microchip maker. As part of this settlement, Apple and Qualcomm need to forego all legal actions worldwide, and the former continues to buy microchips from the latter. With a $2 increase in its latest EPS in early-2019, Qualcomm experiences a 23% share price boost well above $65, and its market capitalization surges by $14.5 billion to more than $83 billion. Qualcomm thus enjoys its best share price performance since 1999. In stark contrast, Apple faces a 3% share price decline, and also the Qualcomm microchip archrival Intel experiences a moderate share price dip.

During the fiscal year from 2018 to early-2019, Apple employs Intel microchips for the iPhone XS and XR production. Apple needs to surpass this strenuous patent settlement with Qualcomm to focus on 5G networks and revolutionary iPhone and iPad functions. With vital access to Intel and Qualcomm microchips, Apple designs 5G iPhones sooner than the late-2020 release date that numerous stock analysts anticipate. The surprise lawsuit settlement represents a *pyrrhic victory* for Apple as Qualcomm inflicts a hard toll on the smartphone bellwether.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Federal Reserve raises the interest rate to the target range of 2.25% to 2.5% as of December 2018.

Charlene Vos

2018-12-22 14:38:00 Saturday ET

Federal Reserve raises the interest rate to the target range of 2.25% to 2.5% as of December 2018.

Federal Reserve raises the interest rate to the target range of 2.25% to 2.5% as of December 2018. Fed Chair Jerome Powell highlights the dovish interest ra

+See More

Analytic business competitors apply smart data science to support their distinctive capabilities and strategic advantages.

Peter Prince

2020-11-24 09:30:00 Tuesday ET

Analytic business competitors apply smart data science to support their distinctive capabilities and strategic advantages.

Many analytic business competitors can apply smart data science to support their distinctive capabilities and strategic advantages. Thomas Davenport and

+See More

President Trump poses new threats to Fed Chair monetary policy independence again.

Apple Boston

2025-06-20 08:27:00 Friday ET

President Trump poses new threats to Fed Chair monetary policy independence again.

President Trump poses new threats to Fed Chair monetary policy independence again. We describe, discuss, and delve into the mainstream reasons, conc

+See More

Most artificial intelligence applications cannot figure out the intricate nuances of natural language and facial recognition.

Fiona Sydney

2019-09-01 10:31:00 Sunday ET

Most artificial intelligence applications cannot figure out the intricate nuances of natural language and facial recognition.

Most artificial intelligence applications cannot figure out the intricate nuances of natural language and facial recognition. These intricate nuances repres

+See More

The U.S. greenback soars in value as the Federal Reserve continues its interest rate hike.

Daisy Harvey

2018-10-07 13:39:00 Sunday ET

The U.S. greenback soars in value as the Federal Reserve continues its interest rate hike.

The U.S. greenback soars in value as the Federal Reserve continues its interest rate hike. With impressive service-sector data and non-farm payroll wage gro

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More